Document is current
Any future updates will be listed below
-
Authors
Chastre, Jean
François, Bruno
Bourgeois, Marc
Komnos, Apostolos
Ferrer, Ricard
Rahav, Galia
De Schryver, Nicolas
Lepape, Alain
Koksal, Iftihar
Luyt, Charles-Edouard
Sánchez-García, Miguel
Torres, Antoni
Eggimann, Philippe
Koulenti, Despoina
Holland, Thomas L.
Ali, Omar
Shoemaker, Kathryn
Ren, Pin
Sauser, Julien
Ruzin, Alexey
Tabor, David E.
Akhgar, Ahmad
Wu, Yuling
Jiang, Yu
DiGiandomenico, Antonio
Colbert, Susan
Vandamme, Drieke
Coenjaerts, Frank
Malhotra-Kumar, Surbhi
Timbermont, Leen
Oliver, Antonio
Barraud, Olivier
Bellamy, Terramika
Bonten, Marc
Goossens, Herman
Reisner, Colin
Esser, Mark T.
Jafri, Hasan S.
,
Joannidis, Michael
Klimscha, Walter
De Waele, Elisabeth
Devriendt, Jacques
Huberlant, Vincent
Depuydt, Pieter
Van Boxstael, Sam
Peric, Mladen
Kopic, Jasminka
Hanauer, Michal
Hruby, Tomas
Sramek, Vladimir
Svoboda, Petr
Vymazal, Tomas
Novacek, Martin
Annane, Djillali
Mira, Jean-Paul
Souweine, Bertrand
Dequin, Pierre-François
Meziani, Ferhat
Stephan, François
Nseir, Saadalla
Gibot, Sebastien
Schwebel, Carole
Plantefeve, Gaetan
Diehl, Jean-Luc
Richard, Christian
Lamer, Christian
Klouche, Kada
Jaber, Samir
Zakynthinos, Epaminondas
Filntisis, Georgios
Zakynthinos, Spyros
Koutsoukou, Antonia
Saroglou, Georgios
Nikolaou, Charikleia
Vlachogianni, Glykeria
Pnevmatikos, Ioannis
Mandragos, Konstantinos
Kremer, Ildiko
Rozgonyi, Zsolt Dezso
Marjanek, Zsuzsa
Martin-Loeches, Ignacio
Singer, Pierre
Van Heerden, Vernon
Carmeli, Yehuda
Povoa, Pedro
Seoane, Antonio Alvarez
Moura, Pedro
Gonzalez, Filipe
Ramirez, Paula
Marti, Antonio Torres
Roca, Ricard Ferrer
Oteiza, Lorena
Escudero, Dolores
Piacentini, Enrique
Vera, Paula
Tamayo, Luis
Gallego, Miguel Angel Gonzalez
Canas, Borja Suberviola
Figueira, Iglesias
Leon, Rafael
Korten, Volkan
Akova, Murat
Wyncoll, Duncan
Whitehouse, Tony
Hopkins, Phil
Sim, Malcolm
Golan, Yoav
Zervos, Marcus
Vazquez, Jose
Cherabuddi, Kartikeya
Smulian, George
Rouphael, Nadine
Welker, James
Sims, Mathew
Van Duin, David
McCarthy, Todd
Polk, Christopher
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02696902 at ClinicalTrials.govDocuments that mention this clinical trial
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
https://doi.org/10.1186/s13054-022-04204-9
-
Funding
Funding for this research was provided by:
Innovative Medicine Initiative Joint Undertaking (115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737, 115737)
- License Information
-
More Information
Article History
Received: 12 September 2022
Accepted: 11 October 2022
First Online: 15 November 2022
Declarations
:
: The study was conducted within the European public–private partnership Combatting Bacterial Resistance In Europe—Molecules Against Gram-Negative Infections (COMBACTE-MAGNET) consortium in accordance with the ethical principles of the Declaration of Helsinki and the International Council for Harmonization Guidance for Good Clinical Practice. Study-related documents were reviewed and approved by the local independent ethics committees or institutional review boards. All subjects/legally acceptable representatives provided written informed consent.
: Not applicable.
: Jean Chastre received personal fees during the conduct of the study from COMBACTE-MAGNET, personal fees from outside of the submitted work from Aridis, Bayer, Inotrem, Shionogi, and Tigenix/Takeda, and grants from AstraZeneca/Medimmune. Bruno François consulted for AM-Pharma, Aridis, Enlivex, GSK, and Inotrem and was part of an adjudication committee for Takeda. Ricard Ferrer received fees for conferences from BD, Grifols, MSD, and Pfizer. Alain Lepape received personal fees outside of the study from Fresenius and Tigenix/Takeda (DSMD committee). Iftihar Koksal has served on advisory boards for Abbvie, MSD, Pfizer, Gilead, GSK, and Roche; lectures: Abbvie, Gilead, Pfizer, and MSD. Charles-Edouard Luyt received fees from Bayer Healthcare, ThermoFisher Brahms, Biomérieux, Faron, Carmat, Aerogen, and Merck Sharp & Dohme outside of the submitted work. Miguel Sánchez-García received funding for speaker fees from Biotest AG, Pfizer, Merck, Sharp & Dohme, AstraZeneca, Orion, and Cepheid; for consulting fees from Bayer, GlaxoSmithKline, Pfizer, and Masimo; for research grants from the European Union, 7th Framework Programme IMI, H2020; was part of an adjudication committee for Takeda. Antoni Torres has served on advisory boards for Pfizer, MSD, Biomérieux, Menarini, Chiesi, and Jansen; lectures: Pfizer and MSD; grants: Bayer, AstraZeneca, and Cardeas. Despoina Koulenti was part of the adjudication committee of EVADE. Thomas L. Holland consulted for Basilea Pharmaceutica, Genentech, and Motif Bio and took part in a Scientific Advisory Board for Motif Bio. Antonio Oliver received grants from and participated as a speaker and in advisory boards for Pfizer, MSD, and Shionogi. Olivier Barraud received speaker fees and/or travel grants from MSD, Pfizer, Roche, and Sanofi and has been a consultant to bioMérieux and Mylan. Herman Goossens received grants from European Union IMI Grant (in collaboration with Novartis). Omar Ali, Ahmad Akhgar, Pin Ren, Terramika Bellamy, Colin Reisner, Alexey Ruzin and Hasan S. Jafri were employees of AstraZeneca during the conduct of the study and hold shares in the company. Kathryn Shoemaker, David E. Tabor, Yuling Wu, Yu Jiang, Antonio DiGiandomenico, Susan Colbert and Mark Esser are employees of AstraZeneca and hold shares in the company. Marc Bourgeois, Apostolos Komnos, Galia Rahav, Nicolas De Schryver, Drieke Vandamme, Surbhi Malhotra-Kumar, Philippe Eggimann, Julien Sauser Frank Coenjaerts, Leen Timbermont, and Marc Bonten have no conflicts of interest to disclose.
